Chronic Kidney Disease and Cerebral Microbleeds: Pathophysiological Insights and Implications for Nephrology [0.03%]
慢性肾脏病与脑微出血：病理生理学见解及其对肾病学的意义
Sang-Hun Lee,Jae-Chan Ryu,Marieta Minasyan et al.
Sang-Hun Lee et al.
Chronic kidney disease (CKD) is an increasing global health burden and is a recognized risk factor for vascular injury. Cerebral microbleeds (CMB), a radiological marker of microvascular hemorrhage in the brain, are more prevalent in CKD an...
Komal Safdar,Palavi Vaidya,Kenzie Johnston et al.
Komal Safdar et al.
Translating Carbamylation Biology into Precision Medicine for Kidney Disease [0.03%]
精准医学视角下的瓜氨酸化生物学与肾脏疾病的关系探究
Aya Awwad,Mengyao Tang,Sahir Kalim
Aya Awwad
Protein carbamylation is a non-enzymatic post-translational protein modification driven by urea-derived cyanate and its reactive form isocyanic acid. Because chronic kidney disease (CKD) is characterized in part by sustained urea retention ...
Erin Vaughan,Vlado Perkovic
Erin Vaughan
A Patient Whose Family Has Experienced Autosomal Dominant Polycystic Kidney Disease for over Four Generations Shares Their Perspective [0.03%]
四代ADPKD家庭患者的就医经历及感悟
Robert Crabtree
Robert Crabtree
Is the Current Practice of Out-of-Sequence Kidney Allocation Justified? Assessing Outcomes, Utility, Efficiency, and Equity [0.03%]
现行的肾脏分配（即先分配给等候名单上优先级最高的患者）是否合理？评估结果、效用、效率和公平性
Beatrice P Concepcion,Yvonne El Kassis,Michelle A Josephson
Beatrice P Concepcion
Fibroblast Growth Factor 23 in CKD: Getting Closer to Prime Time? [0.03%]
慢性肾脏病中的纤维细胞生长因子23：更接近临床应用？
Mandy Wan,Uwe Querfeld,Franz Schaefer et al.
Mandy Wan et al.
Comprehensive Analysis of IgA Nephropathy Causal Factors in Plasma Proteins, Immune Cell Types and Immune Cell Traits [0.03%]
血浆蛋白、免疫细胞类型和免疫细胞特征的IgA肾病致病因素综合分析
Rui-Lian You,Zhi-Ying Liu,Meng-Shi Li et al.
Rui-Lian You et al.
Background: IgA nephropathy (IgAN) remains the most frequent primary glomerular disease worldwide with poor outcomes leading to end-stage kidney disease. Nevertheless, the causal contributions to its pathogenesis are stil...
Effect of Clazakizumab on Neutrophil-Lymphocyte Ratio in Patients Receiving Hemodialysis: Secondary Analysis of the POSIBIL6ESKD Phase 2b Trial [0.03%]
Clazakizumab对接受血液透析患者中性粒细胞/淋巴细胞比率的影响：POSIBIL6ESKD IIb期试验的二次分析
Benjamin Catanese,Mark Heise,Anna M Chang et al.
Benjamin Catanese et al.
How I Treat ESKD with High Volume Hemodiafiltration: Combining Diffusion and Convection as a New Therapy for Outpatients on Dialysis in the US [0.03%]
我如何治疗ESKD并用大容量血液透析滤过：将扩散与对流结合，成为美国门诊透析患者的新型疗法
Anger Michael,Stuard Stefano
Anger Michael